脉衝电场消融市场－全球产业规模、份额、趋势、机会、预测：组成部分、适应症、最终用途、区域及竞争格局（2021-2031年）

全球脉衝电场消融市场预计将从 2025 年的 11.3 亿美元成长到 2031 年的 19.7 亿美元，复合年增长率为 9.71%。

这种非热心导管电气烧灼术技术利用不可逆电穿孔在细胞膜上形成孔隙，有效隔离肺静脉，用于治疗心房颤动。此技术市场成长的主要驱动力在于，与热能消融术相比，其手术时间显着缩短，同时最大限度地减少对周围组织（如膈神经和食道）的损伤。此外，全球心律不整负担的日益加重，也促使人们需要更有效率的电生理检查室工作流程，以满足不断增长的病患需求。

另一方面，主机安装和导管耗材所需的大量初始投资是其在註重成本的医疗机构中广泛应用的主要障碍。儘管有这些经济限制，但在已获得监管部门核准的成熟市场中，临床应用正在加速。欧洲心律协会 (EHRA) 的数据凸显了这一趋势，数据显示，到 2025 年，在接受调查的欧洲医疗机构中，脉衝电场消融将用于 49% 的初始心房颤动消融手术。这项统计数据表明，医疗保健领域对这种先进能量治疗方法的偏好正在显着转变。

市场驱动因素

心房颤动和心律不整的日益普遍是市场成长的主要驱动力，凸显了对脉衝电场消融等先进治疗方法的迫切需求。随着人口老化和生活方式因素导致患者数量不断增加，对有效治疗方法的需求已超过以往的预测，迫使医疗系统采用能够应对更大手术负担的治疗方法。根据山景城地区医疗中心2025年2月的最新预测，美国心房颤动的全国患病人数预计将达到至少1,050万成年人，超过以往的长期预测。为了应对日益增长的负担，采用兼具速度和安全性的脉衝场消融系统至关重要，这将使电生理检查室能够保持高处理能力，并应对不断增长的病例数。

同时，监管核准流程的加速和策略性产品推出正在显着改变竞争格局，并推动脉衝场消融（PFA）技术的快速商业性化应用。领先的医疗科技公司正积极部署PFA平台，随着医师逐渐放弃热能能源来源，这些公司也因此获得了即时的显着收入成长。例如，根据Medical Device Network在2025年10月报道，波士顿科学公司（Boston Scientific）的心血管业务收入在第三季度增长了22.4%，超过33亿美元，这主要归功于其Farapulse系统的强劲市场表现。新兴竞争对手的大量投资也进一步支撑了这项商业性成长动能。例如，根据MedTech Dive在2025年7月报道，Kardium公司成功资金筹措了2.5亿美元，用于支持其Globe脉衝电场消融系统的监管核准和上市。

市场挑战

脉衝电场消融全球市场扩张的主要障碍在于其主机安装和导管耗材所需的大量初始资本支出。儘管该技术具有临床疗效，但购买专用发生器和昂贵的耗材所带来的经济负担，在很大程度上限制了其应用，目前仅限于资金雄厚的学术机构和私人医疗机构。对于预算通常固定、对成本较为敏感地区的区域医院和医疗系统而言，与摊销式热消融系统相比，这种新型治疗方式的价格更高，难以承受。因此，医院管理者不得不严格评估投资报酬率，并常常推迟采购，直到报销模式能够承受更高的营运成本。

治疗费用上的这种差异显着阻碍了这项技术在广大市场中作为标准治疗替代方案的广泛应用。根据心律学会引用的一项2024年真实世界对比分析，脉衝电场消融术的总费用中位数约为10,010英镑，远高于冷冻球囊消融术的8,106英镑，这一差异主要归因于设备和耗材的高价。这种成本差异为采购部门带来了巨大的价值提案，限制了这项技术的市场渗透，使其仅限于能够承担额外成本的医疗机构或拥有特定高额报销协议的机构。

市场趋势

脉衝场消融术（PFA）与先进的三维电解剖标测系统的结合，从根本上重塑了手术环境，克服了早期单次消融设备在可视化方面的限制。製造商正致力于开发能够与其专有标测平台无缝整合的导管，使电生理学家能够在能量输送过程中即时监测导管位置和组织接触指标。这种技术协同作用提高了消融病灶的精确性和安全性，有助于治疗盲目导管定位不足以应对的复杂心律不整。根据TCTMD于2025年12月报道，Volt脉衝电场消融系统获得FDA核准，其临床数据显示，该系统在阵发性心房颤动患者中实现了93.1%的心律不整復发率，如此高的成功率主要归功于该系统的即时接触可视化功能。

此外，将临床适应症扩展至室性心搏过速，标誌着市场成长的重大进展。电穿孔的组织选择性使其能够用于治疗高危险心室心律不整。与热疗不同，后者在深部室性消融过程中存在损伤敏感心臟结构的风险，而脉衝场能量能够穿透厚厚的室性疤痕组织而不造成附带损伤，因此安全性更高。这项潜力推动了积极的研究工作，旨在将脉衝场消融术（PFA）确立为危及生命的心室心律不整的标准治疗方法，从而显着扩大了目标患者群体，使其不再局限于房颤。根据2025年4月在心臟节律学会会议上发表的报告，首个人体室性心律不整消融系统（VCAS）试验的结果显示，一种特殊接触力PFA系统实现了78%的瘢痕相关性室性心动过速发生率，这支持了该技术有望改变这一复杂领域的治疗结果。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球脉衝电场消融市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按组件（导管、发生器）
  • 适应症（心房颤动、非心房颤动）
  • 依最终用途（住院、门诊病人）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美脉衝电场消融市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲脉衝电场消融市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区脉衝电场消融市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲脉衝电场消融市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美脉衝电场消融市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球脉衝电场消融市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boston Scientific Corporation
• Abbott Laboratories Inc.
• Medtronic, Inc.
• Biosense Webster, Inc.
• Adagio Medical Inc.
• Kardium Inc.
• Pulse Biosciences, Inc.
• CardioFocus, Inc.
• Acutus Medical, Inc.
• Field Medical, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pulsed Field Ablation Market is projected to expand from USD 1.13 Billion in 2025 to USD 1.97 Billion by 2031, registering a CAGR of 9.71%. This nonthermal cardiac ablation technique utilizes irreversible electroporation to create pores in cell membranes, effectively isolating pulmonary veins for the treatment of atrial fibrillation. Market growth is largely propelled by the technology's capacity to minimize injury to collateral structures, such as the phrenic nerve and esophagus, while delivering significantly faster procedure times than thermal energy alternatives. Furthermore, the escalating global burden of arrhythmias is driving the need for more efficient electrophysiology laboratory workflows to accommodate increasing patient volumes.

Conversely, the substantial initial capital investment required for console installation and catheter consumables poses a major obstacle to widespread implementation in cost-conscious healthcare settings. Despite these financial constraints, clinical adoption is accelerating in established markets following regulatory clearances. Data from the European Heart Rhythm Association highlights this trend, revealing that in 2025, Pulsed Field Ablation was employed in 49% of initial atrial fibrillation ablation procedures across surveyed European centers. This statistic underscores a significant transition in medical preference towards this advanced energy modality.

Market Driver

The increasing prevalence of atrial fibrillation and cardiac arrhythmias acts as a primary engine for market growth, creating a critical need for advanced interventions such as Pulsed Field Ablation. As aging populations and lifestyle factors contribute to swelling patient numbers, the demand for effective treatments has surpassed historical estimates, compelling healthcare systems to identify modalities capable of managing higher procedural loads. According to MountainView Regional Medical Center's February 2025 update, the estimated national prevalence of atrial fibrillation in the United States has risen to at least 10.5 million adults, exceeding previous long-term forecasts. This growing burden necessitates the adoption of PFA systems that provide both speed and safety, ensuring electrophysiology labs can maintain high throughput to handle the rising caseload.

Simultaneously, the acceleration of regulatory approvals and strategic product launches has significantly altered the competitive landscape and driven rapid commercial adoption. Leading medical technology companies are aggressively rolling out their PFA platforms, leading to immediate and considerable revenue gains as physicians shift away from thermal energy sources. For instance, Medical Device Network reported in October 2025 that Boston Scientific achieved a 22.4% rise in cardiovascular business revenue, surpassing $3.3 billion in the third quarter, a growth largely credited to the strong adoption of its Farapulse system. This commercial momentum is further illustrated by substantial investments in emerging competitors, such as Kardium, which, according to MedTech Dive in July 2025, secured $250 million to support the regulatory approval and launch of its Globe pulsed field ablation system.

Market Challenge

The significant initial capital expenditure necessary for console installation and catheter consumables represents a major hurdle to the expansion of the Global Pulsed Field Ablation Market. Although the technology delivers clinical efficiency, the financial strain of purchasing proprietary generators and costly single-use devices largely restricts adoption to well-funded academic centers and private institutions. Community hospitals and healthcare systems in cost-sensitive areas often function on fixed budgets that cannot support the premium pricing of this new modality when compared to fully amortized thermal ablation systems. Consequently, hospital administrators are forced to rigorously evaluate the return on investment, frequently postponing procurement until reimbursement models better accommodate the higher operational expenses.

This discrepancy in procedural costs significantly impedes the technology's capacity to replace standard-of-care treatments within the broader market. A 2024 real-world comparative analysis cited by the Heart Rhythm Society revealed that Pulsed Field Ablation procedures carried a notably higher median total cost of roughly £10,010, compared to £8,106 for cryoballoon ablation, a difference largely resulting from the premium prices of equipment and disposables. This cost gap establishes a challenging value proposition for purchasing departments, limiting the technology's market penetration to facilities capable of absorbing the added expense or those holding specific high-tier reimbursement contracts.

Market Trends

The integration of PFA with advanced 3D electroanatomical mapping systems is fundamentally reshaping the procedural environment by overcoming the visualization constraints associated with early single-shot devices. Manufacturers are increasingly focusing on developing catheters that interface seamlessly with proprietary mapping platforms, enabling electrophysiologists to monitor real-time catheter location and tissue contact metrics during energy delivery. This technological synergy improves lesion precision and safety, aiding in the treatment of complex arrhythmias where blind catheter positioning proves inadequate. As reported by TCTMD in December 2025, the FDA approval of the Volt pulsed-field ablation system was underpinned by clinical data showing a 93.1% freedom from arrhythmia recurrence in patients with paroxysmal atrial fibrillation, a high efficacy rate largely credited to the system's real-time contact visualization capabilities.

Furthermore, the expansion of clinical indications to include ventricular tachycardia represents a crucial frontier for market growth, utilizing the tissue-selective properties of electroporation to manage high-risk ventricular arrhythmias. Unlike thermal modalities, which risk damaging sensitive cardiac structures during deep ventricular burns, pulsed field energy provides a safer profile for penetrating thick ventricular scar tissue without causing collateral injury. This potential is stimulating robust investigational efforts to establish PFA as a standard treatment for life-threatening ventricular rhythm disorders, thereby significantly widening the addressable patient base beyond atrial fibrillation. According to the Heart Rhythm Society in April 2025, results from the First-in-Human VCAS Trial demonstrated that a specialized contact force PFA system achieved a 78% rate of freedom from scar-related ventricular tachycardia, underscoring the modality's potential to transform outcomes in this difficult therapeutic area.

Key Market Players

• Boston Scientific Corporation
• Abbott Laboratories Inc.
• Medtronic, Inc.
• Biosense Webster, Inc.
• Adagio Medical Inc.
• Kardium Inc.
• Pulse Biosciences, Inc.
• CardioFocus, Inc.
• Acutus Medical, Inc.
• Field Medical, Inc.

Report Scope

In this report, the Global Pulsed Field Ablation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pulsed Field Ablation Market, By Components

• Catheters
• Generators

Pulsed Field Ablation Market, By Indication

• Atrial Fibrillation
• Non-Atrial Fibrillation

Pulsed Field Ablation Market, By End Use

• Inpatient
• Outpatient

Pulsed Field Ablation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pulsed Field Ablation Market.

Available Customizations:

Global Pulsed Field Ablation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pulsed Field Ablation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Components (Catheters, Generators)
  • 5.2.2. By Indication (Atrial Fibrillation, Non-Atrial Fibrillation)
  • 5.2.3. By End Use (Inpatient, Outpatient)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pulsed Field Ablation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Components
  • 6.2.2. By Indication
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pulsed Field Ablation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Components
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Pulsed Field Ablation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Components
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Pulsed Field Ablation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Components
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End Use

7. Europe Pulsed Field Ablation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Components
  • 7.2.2. By Indication
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pulsed Field Ablation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Components
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Pulsed Field Ablation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Components
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Pulsed Field Ablation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Components
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Pulsed Field Ablation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Components
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Pulsed Field Ablation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Components
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End Use

8. Asia Pacific Pulsed Field Ablation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Components
  • 8.2.2. By Indication
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pulsed Field Ablation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Components
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Pulsed Field Ablation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Components
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Pulsed Field Ablation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Components
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Pulsed Field Ablation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Components
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Pulsed Field Ablation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Components
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Pulsed Field Ablation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Components
  • 9.2.2. By Indication
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pulsed Field Ablation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Components
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Pulsed Field Ablation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Components
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Pulsed Field Ablation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Components
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End Use

10. South America Pulsed Field Ablation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Components
  • 10.2.2. By Indication
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pulsed Field Ablation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Components
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Pulsed Field Ablation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Components
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Pulsed Field Ablation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Components
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pulsed Field Ablation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Medtronic, Inc.
• 15.4. Biosense Webster, Inc.
• 15.5. Adagio Medical Inc.
• 15.6. Kardium Inc.
• 15.7. Pulse Biosciences, Inc.
• 15.8. CardioFocus, Inc.
• 15.9. Acutus Medical, Inc.
• 15.10. Field Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer